Lixte Biotech Hlds
(LIXT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,888 | 887 | 1,385 | 1,039 | 1,638 |
| Other current assets | 2,455 | 0 | 0 | 0 | 0 |
| TOTAL | $5,434 | $990 | $1,514 | $1,146 | $1,689 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 199 | 0 | 0 | 7 |
| TOTAL | $N/A | $199 | $N/A | $N/A | $7 |
| Total Assets | $5,434 | $1,189 | $1,514 | $1,146 | $1,696 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 236 | 92 | 113 | 83 | 73 |
| Accrued Expenses | N/A | 189 | N/A | N/A | N/A |
| Other current liabilities | 286 | 256 | 243 | 235 | 256 |
| TOTAL | $521 | $537 | $355 | $318 | $329 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $521 | $537 | $355 | $318 | $329 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 5,704 | 4,561 | 2,684 | 2,684 | 2,249 |
| Common Shares | 1 | 0 | 0 | 0 | 0 |
| Retained earnings | -55,533 | -53,553 | -52,777 | -52,068 | -51,450 |
| TOTAL | $4,912 | $652 | $1,159 | $827 | $1,367 |
| Total Liabilities And Equity | $5,434 | $1,189 | $1,514 | $1,146 | $1,696 |